Background

: The Oxford Depression Questionnaire (ODQ) is a patient-reported scale for assessing emotional blunting in patients with major depressive disorder (MDD). This analysis was undertaken to further validate the scale in patients experiencing emotional blunting while receiving antidepressant treatment.

Methods

: Patients with MDD who experienced inadequate depressive-symptom resolution and emotional blunting on selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor monotherapy (adequate dose for ≥6 weeks) were switched to vortioxetine 10–20 mg/day. ODQ total scores were assessed excluding and including the “antidepressant-as-cause” domain (ODQ-20 and ODQ-26, respectively). Anchor- and distribution-based methods were used to determine the minimal clinically important difference in ODQ scores.

Results

: After 8 weeks of vortioxetine treatment, the mean change in ODQ-20 and ODQ-26 scores from baseline was −24.8 and −30.1 points, respectively. Greater mean changes from baseline in ODQ-20 and ODQ-26 scores were seen in patients reporting no emotional blunting vs those still experiencing emotional blunting after 8 weeks of vortioxetine (ODQ-20: −27.0 vs −22.6 points; ODQ-26: –32.8 vs –27.5 points, respectively). In patients considered minimally improved (Clinical Global Impression–Improvement score, 3) after 8 weeks of vortioxetine, respective mean (standard deviation) change in ODQ-20 and ODQ-26 score from baseline was −15.5 (18.1) and –20.0 (20.5) points.

Limitations

: Short study duration.

Conclusions

: These results provide further validation of the clinical utility of the ODQ for assessing emotional blunting in patients with MDD. The suggested minimal clinically important difference for ODQ-20 and ODQ-26 scores is 16 and 20 points, respectively.

Trial registration

: ClinicalTrials.gov identifier: NCT03835715.

中文翻译：

---

牛津抑郁问卷的验证：对变化的敏感性、最小的临床重要差异和情绪迟钝评估的反应阈值

背景

：牛津抑郁症问卷 (ODQ) 是一种患者报告的量表，用于评估重度抑郁症 (MDD) 患者的情绪迟钝程度。进行这项分析是为了进一步验证在接受抗抑郁治疗时情绪迟钝的患者的量表。

方法

：在选择性 5-羟色胺再摄取抑制剂或 5-羟色胺-去甲肾上腺素再摄取抑制剂单药治疗（足够剂量≥6 周）中出现抑郁症状缓解不足和情绪迟钝的 MDD 患者改用 vortioxetine 10-20 mg/天。ODQ 总分的评估不包括和包括“抗抑郁药作为原因”域（分别为 ODQ-20 和 ODQ-26）。使用基于锚点和分布的方法来确定 ODQ 分数的最小临床重要差异。

结果

：在沃替西汀治疗 8 周后，ODQ-20 和 ODQ-26 评分相对于基线的平均变化分别为 -24.8 和 -30.1 分。与服用沃替西汀 8 周后报告没有情绪迟钝的患者相比，ODQ-20 和 ODQ-26 评分与基线相比的平均变化更大（ODQ-20：-27.0 比 -22.6 分；ODQ-26：-分别为 32.8 和 –27.5 分）。在沃替西汀 8 周后被认为有最小改善（临床总体印象-改善评分，3）的患者中，ODQ-20 和 ODQ-26 评分相对于基线的平均（标准差）变化分别为 -15.5 (18.1) 和 –20.0 (20.5) ) 点。

限制

: 学习时间短。

结论

：这些结果进一步验证了 ODQ 在评估 MDD 患者情绪迟钝方面的临床效用。ODQ-20 和 ODQ-26 评分的建议最小临床重要差异分别为 16 分和 20 分。

试用注册

：ClinicalTrials.gov 标识符：NCT03835715。